Malaysia To Procure Merck's Covid-19 Pills That Reduce Deaths & Hospitalisations By Half
Health Minister, Khairy Jamaluddin announced on Twitter that Putrajaya is in talks to procure an experimental antiviral drug for Covid-19 treatment, after a study revealed that the pills were able to reduce deaths and hospitalisation rates by half.
“As we transition to living with COVID we will be adding new, innovative treatment options to our arsenal in addition to vaccines. I have already started negotiating for Malaysia to procure these effective drugs that have gone through clinical trials,” Khairy tweeted.
US-based Merck & Co pills uses molnupiravir, which is designed to introduce errors into the genetic code of the virus. Merck and partner Ridgeback Biotherapeutics said that they plan to get US authorisation for emergency use of the pills as soon as possible and to make regulatory applications worldwide.
Senior scholar at the Johns Hopkins Center for Health Security, Amesh Adalja said that an oral antiviral that can impact hospitalisation risk to such a degree would be “game-changing.”